{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T01:31:01Z","timestamp":1786325461482,"version":"build-2736575974"},"reference-count":101,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Cancer remains one of the leading causes of morbidity and mortality worldwide despite advances in molecular oncology and targeted therapeutics. The growing demand for precision medicine has accelerated the development of radiotheranostics, an emerging paradigm that integrates molecular imaging and targeted radionuclide therapy. In parallel, medicinal chemistry continues to generate structurally diverse small-molecule scaffolds capable of modulating key oncogenic pathways. Increasing evidence indicates that certain chemical scaffolds possess intrinsic properties that extend beyond conventional anticancer activity and support their translation into radiotheranostic applications. This review examines major scaffold classes driving contemporary anticancer drug discovery, including thiosemicarbazones, heterocyclic compounds, metal-based agents, hybrid molecules, and multifunctional platforms. Particular attention is given to the structural features governing biological activity, target selectivity, metal coordination, and radiolabeling potential. The review further highlights the mechanistic convergence between scaffold-mediated anticancer effects and radionuclide-induced cytotoxicity, emphasizing shared pathways involving DNA damage, oxidative stress, inhibition of DNA repair, and modulation of oncogenic signaling. Based on these observations, a scaffold-centered framework for radiotheranostic development is proposed, with perspectives on hybrid molecular design, copper-based theranostic systems, and artificial intelligence-assisted ligand discovery. By integrating medicinal chemistry, molecular oncology, and nuclear medicine, this review outlines structural principles that may facilitate the rational design of next-generation precision anticancer agents and radiotheranostic platforms.<\/jats:p>","DOI":"10.3390\/ph19081248","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T01:20:03Z","timestamp":1786324803000},"page":"1248","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chemical Scaffolds Driving Modern Anticancer Drug Discovery and Radiotheranostics: Structural Determinants, Translational Opportunities and Future Perspectives"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9592-2478","authenticated-orcid":false,"given":"Marta","family":"Rusek","sequence":"first","affiliation":[{"name":"Independent Unit of Radiopharmacy, Faculty of Pharmacy, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_3","first-page":"12","article-title":"Cancer Statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13073-019-0703-1","article-title":"Molecular Profiling for Precision Cancer Therapies","volume":"12","author":"Malone","year":"2020","journal-title":"Genome Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Yazdani, E., Geramifar, P., Karamzade-Ziarati, N., Sadeghi, M., Amini, P., and Rahmim, A. (2024). Radiomics and Artificial Intelligence in Radiotheranostics: A Review of Applications for Radioligands Targeting Somatostatin Receptors and Prostate-Specific Membrane Antigens. Diagnostics, 14.","DOI":"10.3390\/diagnostics14020181"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"117535","DOI":"10.1016\/j.ejmech.2025.117535","article-title":"Mechanistic Study of Cancer Drug Delivery: Current Techniques, Limitations, and Future Prospects","volume":"290","author":"Imtiaz","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cbpa.2010.02.018","article-title":"Privileged Scaffolds for Library Design and Drug Discovery","volume":"14","author":"Welsch","year":"2010","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1021\/acs.jmedchem.6b01437","article-title":"Recent Advances in Scaffold Hopping","volume":"60","author":"Hu","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kumar, A., Singh, A.K., Singh, H., Vijayan, V., Kumar, D., Naik, J., Thareja, S., Yadav, J.P., Pathak, P., and Grishina, M. (2023). Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective. Pharmaceuticals, 16.","DOI":"10.3390\/ph16020299"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9594","DOI":"10.1021\/acs.jmedchem.5c00374","article-title":"Advantages of Novel Anti-Cancer Selenosemicarbazones: Preferential Reactivity of Their Fe(III), Cu(II), and Zn(II) Complexes with Key Physiological Reductants\/Ligands Versus Isosteric Thiosemicarbazones","volume":"68","author":"Dharmasivam","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"130152","DOI":"10.1016\/j.bbagen.2022.130152","article-title":"The Thiosemicarbazone, DpC, Broadly Synergizes with Multiple Anti-Cancer Therapeutics and Demonstrates Temperature- and Energy-Dependent Uptake by Tumor Cells","volume":"1866","author":"Dharmasivam","year":"2022","journal-title":"Biochim. Biophys. Acta (BBA)-Gen. Subj."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2147\/DDDT.S170879","article-title":"Copper-64: A Real Theranostic Agent","volume":"12","author":"Gutfilen","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Krasnovskaya, O.O., Abramchuck, D., Erofeev, A., Gorelkin, P., Kuznetsov, A., Shemukhin, A., and Beloglazkina, E.K. (2023). Recent Advances in 64Cu\/67Cu-Based Radiopharmaceuticals. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119154"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1021\/acs.jmedchem.4c02885","article-title":"Radiocopper in Radiopharmacy and Medical Use: Current Status and Perspective","volume":"68","author":"Pitucha","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12964-024-01607-9","article-title":"Potentials and Future Perspectives of Multi-Target Drugs in Cancer Treatment: The next Generation Anti-Cancer Agents","volume":"22","author":"Doostmohammadi","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-024-02041-6","article-title":"Radiopharmaceuticals and Their Applications in Medicine","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S1470-2045(19)30821-6","article-title":"Radiotheranostics: A Roadmap for Future Development","volume":"21","author":"Herrmann","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Sandhu, K., Chen, D., Hennes, D., Murphy, D.G., Lawrentschuk, N., and Perera, M. (2025). PSMA Theranostics in Prostate Cancer and Beyond: Current and Future Perspectives. Cancers, 17.","DOI":"10.3390\/cancers17223717"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Jones, W., Griffiths, K., Barata, P.C., and Paller, C.J. (2020). PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy. Cancers, 12.","DOI":"10.3390\/cancers12061367"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Czuczejko, J., Ma\u0142kowski, B., Nuszkiewicz, J., Ho\u0142y\u0144ska-Iwan, I., Wa\u015bniowski, P., M\u0105dra-Gackowska, K., Dr\u00f3\u017cd\u017c, W., and Szewczyk-Golec, K. (2026). Radiolabelled FAPI Radiotracers in Oncology: A Comprehensive Review of Current Diagnostic and Emerging Therapeutic Applications. Pharmaceuticals, 19.","DOI":"10.3390\/ph19010089"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"20180440","DOI":"10.1259\/bjr.20180440","article-title":"An Introduction to the Clinical Practice of Theranostics in Oncology","volume":"91","author":"Turner","year":"2018","journal-title":"Br. J. Radiol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Werner, R.A., Higuchi, T., Pomper, M.G., and Rowe, S.P. (2021). Theranostics in Oncology\u2014Thriving, Now More than Ever. Diagnostics, 11.","DOI":"10.3390\/diagnostics11050805"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00259-025-07617-0","article-title":"Safety and Efficacy of 177Lu-FAPI-XT Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities: First-in-Human, Dose-Escalation Study","volume":"53","author":"Liu","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1007\/s00259-025-07103-7","article-title":"Radiotheranostic Landscape: A Review of Clinical and Preclinical Development","volume":"52","author":"Tran","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Palihati, M., Das, J.P., Yeh, R., and Capaccione, K. (2025). Emerging PET Imaging Agents and Targeted Radioligand Therapy: A Review of Clinical Applications and Trials. Tomography, 11.","DOI":"10.3390\/tomography11080083"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.7150\/thno.92612","article-title":"PSMA-Targeted Radiotheranostics in Modern Nuclear Medicine: Then, Now, and What of the Future?","volume":"14","author":"Sallam","year":"2024","journal-title":"Theranostics"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s12149-025-02090-z","article-title":"Recent Advances in Theranostics and Oncology PET: Emerging Radionuclides and Targets","volume":"39","author":"Watabe","year":"2025","journal-title":"Ann. Nucl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Singh, A.K., Kumar, A., Singh, H., Sonawane, P., Paliwal, H., Thareja, S., Pathak, P., Grishina, M., Jaremko, M., and Emwas, A.-H. (2022). Concept of Hybrid Drugs and Recent Advancements in Anticancer Hybrids. Pharmaceuticals, 15.","DOI":"10.3390\/ph15091071"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.2174\/1568026616666160927160620","article-title":"Hybrid Compounds as Direct Multitarget Ligands: A Review","volume":"17","author":"Ishiki","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1021\/jm00120a002","article-title":"Methods for Drug Discovery: Development of Potent, Selective, Orally Effective Cholecystokinin Antagonists","volume":"31","author":"Evans","year":"1988","journal-title":"J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"102932","DOI":"10.1016\/j.rechem.2025.102932","article-title":"Heterocyclic Compounds with Diverse Biological Activities: A Review of Quinazoline and Quinazolinone Derivatives","volume":"19","author":"Kalakwade","year":"2026","journal-title":"Results Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"31557","DOI":"10.1039\/D6RA02591A","article-title":"Privileged Nitrogen Heterocycles in Anticancer Drug Discovery: Recent Advances on Imidazole, Indole, and Pyrimidine Scaffolds","volume":"16","author":"Govindarajan","year":"2026","journal-title":"RSC Adv."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Nitulescu, G.M., Stancov, G., Seremet, O.C., Nitulescu, G., Mihai, D.P., Duta-Bratu, C.G., Barbuceanu, S.F., and Olaru, O.T. (2023). The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies. Molecules, 28.","DOI":"10.3390\/molecules28145359"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"K R, K., Hacholli, V.B., Gackowski, M., Pisklak, D.M., Kumar, A., and Szeleszczuk, \u0141. (2026). The Pyrazole Scaffold in Anticancer Drug Discovery: A Review of Synthetic Approaches, Structure\u2013Activity Relationships, and Target-Based Mechanism of Action. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27083403"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","article-title":"Cyclin-Dependent Protein Serine\/Threonine Kinase Inhibitors as Anticancer Drugs","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"10257","DOI":"10.1021\/jm501100b","article-title":"Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals","volume":"57","author":"Vitaku","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ica.2012.02.019","article-title":"Metal Complexes of Thiosemicarbazones for Imaging and Therapy","volume":"389","author":"Dilworth","year":"2012","journal-title":"Inorganica Chim. Acta"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1039\/C3CS60304K","article-title":"Matching Chelators to Radiometals for Radiopharmaceuticals","volume":"43","author":"Price","year":"2014","journal-title":"Chem. Soc. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular Properties That Influence the Oral Bioavailability of Drug Candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Acosta-Murillo, R., Ortiz-Bayliss, J.C., and Zapata-Morin, P.A. (2026). Enhancing Cancer Drug Discovery: QSAR Modeling with Machine Learning and Chemical Representations. PLoS ONE, 21.","DOI":"10.1371\/journal.pone.0343654"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Alsibaee, A.M., Al-Yousef, H.M., and Al-Salem, H.S. (2023). Quinazolinones, the Winning Horse in Drug Discovery. Molecules, 28.","DOI":"10.3390\/molecules28030978"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR Antagonists in Cancer Treatment","volume":"358","author":"Fortunato","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Abdel-Mohsen, H.T., Anwar, M.M., Ahmed, N.S., Abd El-Karim, S.S., and Abdelwahed, S.H. (2024). Recent Advances in Structural Optimization of Quinazoline-Based Protein Kinase Inhibitors for Cancer Therapy (2021\u2013Present). Molecules, 29.","DOI":"10.3390\/molecules29040875"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1021\/ci700418f","article-title":"Scaffold Hopping in Drug Discovery Using Inductive Logic Programming","volume":"48","author":"Tsunoyama","year":"2008","journal-title":"J. Chem. Inf. Model."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s42003-023-05254-7","article-title":"Molecular Hybridization Strategy for Tuning Bioactive Peptide Function","volume":"6","author":"Pedron","year":"2023","journal-title":"Commun. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/ar7000843","article-title":"Hybrid Molecules with a Dual Mode of Action: Dream or Reality?","volume":"41","author":"Meunier","year":"2008","journal-title":"Acc. Chem. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/cac2.70063","article-title":"Advances in Radiopharmaceuticals for Cancer Radiotheranostics: CCK2R Targeting as a Paradigm for Translational Innovation","volume":"45","author":"Li","year":"2025","journal-title":"Cancer Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e202500676","DOI":"10.1002\/cbic.202500676","article-title":"Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management","volume":"27","author":"Shaikh","year":"2026","journal-title":"ChemBioChem"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed Multiple Ligands. An Emerging Drug Discovery Paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1186\/s40169-017-0181-2","article-title":"A Perspective on Multi-Target Drug Discovery and Design for Complex Diseases","volume":"7","author":"Ramsay","year":"2018","journal-title":"Clin. Transl. Med."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Czylkowska, A., Pitucha, M., Raducka, A., Fornal, E., Kordialik-Bogacka, E., \u015acieszka, S., Smoluch, M., Burdan, F., J\u0119drzejec, M., and Szyma\u0144ski, P. (2025). Thiosemicarbazone-Based Compounds: A Promising Scaffold for Developing Antibacterial, Antioxidant, and Anticancer Therapeutics. Molecules, 30.","DOI":"10.3390\/molecules30010129"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Garbuz, O., Ceban, E., Istrati, D., Railean, N., Toderas, I., and Gulea, A. (2025). Thiosemicarbazone-Based Compounds: Cancer Cell Inhibitors with Antioxidant Properties. Molecules, 30.","DOI":"10.3390\/molecules30092077"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1038\/s41598-025-33889-5","article-title":"Design and Biological Evaluation of Novel Water-Soluble Complexes Based on Thiosemicarbazone as Prospective Anticancer Agents","volume":"16","author":"Feizpour","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.bbagen.2008.04.003","article-title":"Cancer Cell Iron Metabolism and the Development of Potent Iron Chelators as Anti-Tumour Agents","volume":"1790","author":"Richardson","year":"2009","journal-title":"Biochim. Biophys. Acta (BBA)-Gen. Subj."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.phrs.2015.08.013","article-title":"The Renaissance of Polypharmacology in the Development of Anti-Cancer Therapeutics: Inhibition of the \u201cTriad of Death\u201d in Cancer by Di-2-Pyridylketone Thiosemicarbazones","volume":"100","author":"Jansson","year":"2015","journal-title":"Pharmacol. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd2803","article-title":"Targeting Cancer Cells by ROS-Mediated Mechanisms: A Radical Therapeutic Approach?","volume":"8","author":"Trachootham","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/blood-2004-05-1866","article-title":"Iron Chelators with High Antiproliferative Activity Up-Regulate the Expression of a Growth Inhibitory and Metastasis Suppressor Gene: A Link between Iron Metabolism and Proliferation","volume":"104","author":"Le","year":"2004","journal-title":"Blood"},{"key":"ref_59","first-page":"177","article-title":"Evaluation of 64Cu-ATSM In Vitro and In Vivo in a Hypoxic Tumor Model","volume":"40","author":"Lewis","year":"1999","journal-title":"J. Nucl. Med."},{"key":"ref_60","first-page":"1155","article-title":"Copper-62-ATSM: A New Hypoxia Imaging Agent with High Membrane Permeability and Low Redox Potential","volume":"38","author":"Fujibayashi","year":"1997","journal-title":"J. Nucl. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.ejmech.2014.11.059","article-title":"Recent Advances in Bioactive Pyrazoles","volume":"97","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/S0960-894X(01)00344-4","article-title":"Studies Leading to the Identification of ZD1839 (IressaTM): An Orally Active, Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Targeted to the Treatment of Cancer","volume":"11","author":"Barker","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological Determinants of PSMA Expression, Regulation and Heterogeneity in Prostate Cancer","volume":"22","author":"Bakht","year":"2025","journal-title":"Nat. Rev. Urol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e240080","DOI":"10.1148\/rg.240080","article-title":"PSMA Radiotheranostics in Prostate Cancer: Principles, Practice, and Future Prospects","volume":"44","author":"Szidonya","year":"2024","journal-title":"RadioGraphics"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1158\/0008-5472.CAN-11-1218","article-title":"Antitumor Activity of Metal-Chelating Compound Dp44mT Is Mediated by Formation of a Redox-Active Copper Complex That Accumulates in Lysosomes","volume":"71","author":"Lovejoy","year":"2011","journal-title":"Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm2007613","article-title":"Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal\u2013Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)","volume":"54","author":"Cui","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"112946","DOI":"10.1016\/j.ejmech.2020.112946","article-title":"Pyridazine as a Privileged Structure: An Updated Review on Anticancer Activity of Pyridazine Containing Bioactive Molecules","volume":"209","author":"He","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"117847","DOI":"10.1016\/j.bmc.2024.117847","article-title":"Recent Contributions of Pyridazine as a Privileged Scaffold of Anticancer Agents in Medicinal Chemistry: An Updated Review","volume":"111","author":"Liu","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.bmc.2013.01.074","article-title":"Discovery of N-[5-(2-[(Cyclopropylcarbonyl)Amino]Imidazo[1,2-b]Pyridazin-6-Yloxy)-2-Methylphenyl]-1,3-Dimethyl-1H-Pyrazole-5-Carboxamide (TAK-593), a Highly Potent VEGFR2 Kinase Inhibitor","volume":"21","author":"Miyamoto","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/14756366.2022.2135512","article-title":"Biological Evaluation, Docking Studies, and in Silico ADME Prediction of Some Pyrimidine and Pyridine Derivatives as Potential EGFRWT and EGFRT790M Inhibitors","volume":"38","author":"Elmaaty","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or Carboplatin\u2013Paclitaxel in Pulmonary Adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.112.197756","article-title":"Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker","volume":"343","author":"Solca","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ejmech.2014.03.018","article-title":"Rational Approaches, Design Strategies, Structure Activity Relationship and Mechanistic Insights for Anticancer Hybrids","volume":"77","author":"Nepali","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s41181-025-00364-5","article-title":"Exploring the Radiochemistry of PARP Inhibitors: A New Era in Therapy and Imaging","volume":"10","author":"Destro","year":"2025","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2967\/jnumed.118.213223","article-title":"PET Imaging of PARP Expression Using 18F-Olaparib","volume":"60","author":"Wilson","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/ejic.201600986","article-title":"Thirty Years of the Drug Candidate NAMI-A and the Myths in the Field of Ruthenium Anticancer Compounds: A Personal Perspective","volume":"2017","author":"Alessio","year":"2017","journal-title":"Eur. J. Inorg. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/jm100020w","article-title":"Organometallic Anticancer Compounds","volume":"54","author":"Gasser","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ccr.2009.02.019","article-title":"On the Medicinal Chemistry of Gold Complexes as Anticancer Drugs","volume":"253","author":"Ott","year":"2009","journal-title":"Coord. Chem. Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in Vivo Protein Knockdown by Small-Molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC Targeted Protein Degraders: The Past Is Prologue","volume":"21","author":"Langley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/anie.199309501","article-title":"The Role of Chemistry in the Development of Boron Neutron Capture Therapy of Cancer","volume":"32","author":"Hawthorne","year":"1993","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP Inhibitors: Synthetic Lethality in the Clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/onc.2014.155","article-title":"Ribonucleotide Reductase and Cancer: Biological Mechanisms and Targeted Therapies","volume":"34","author":"Aye","year":"2015","journal-title":"Oncogene"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Huff, S.E., Winter, J.M., and Dealwis, C.G. (2022). Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present. Biomolecules, 12.","DOI":"10.3390\/biom12060815"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus Cabazitaxel in Patients with Metastatic Castration-Resistant Prostate Cancer (TheraP): A Randomised, Open-Label, Phase 2 Trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Serumula, W., Pillay, V., Hadebe, B., and Vorster, M. (2025). Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics. Pharmaceuticals, 18.","DOI":"10.3390\/ph18040522"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s12149-025-02022-x","article-title":"FAPI Radiopharmaceuticals in Nuclear Oncology and Theranostics of Solid Tumours: Are We Nearer to Surrounding the Hallmarks of Cancer?","volume":"39","author":"Almeida","year":"2025","journal-title":"Ann. Nucl. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.drudis.2018.04.002","article-title":"The Emerging Role of Copper-64 Radiopharmaceuticals as Cancer Theranostics","volume":"23","author":"Boschi","year":"2018","journal-title":"Drug Discov. Today"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1021\/cr3003104","article-title":"Radiometals for Combined Imaging and Therapy","volume":"113","author":"Cutler","year":"2013","journal-title":"Chem. Rev."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nchem.1243","article-title":"Quantifying the Chemical Beauty of Drugs","volume":"4","author":"Bickerton","year":"2012","journal-title":"Nat. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/MNM.0000000000002011","article-title":"The Current Status and Promising Potential of Copper-Based Radiopharmaceutical Development towards Future Theranostics: An Overview","volume":"46","author":"Baberwal","year":"2025","journal-title":"Nucl. Med. Commun."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.7150\/thno.106108","article-title":"Therapeutic Potential of FAPI RLT in Oncology: A Systematic Review","volume":"15","author":"Ruzzeh","year":"2025","journal-title":"Theranostics"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in Oncology: Current Challenges and Emerging Opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1124\/mol.111.073627","article-title":"Novel Thiosemicarbazone Iron Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-Myc Down-Stream Regulated Gene 1: A New Strategy for the Treatment of Pancreatic Cancer","volume":"80","author":"Kovacevic","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e220157","DOI":"10.1148\/rycan.220157","article-title":"A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements","volume":"5","author":"Burkett","year":"2023","journal-title":"Radiol. Imaging Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1021\/acs.chemrev.3c00778","article-title":"Theranostic Fluorescent Probes","volume":"124","author":"Sharma","year":"2024","journal-title":"Chem. Rev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"23889","DOI":"10.1021\/acsomega.5c00549","article-title":"AI-Driven Drug Discovery: A Comprehensive Review","volume":"10","author":"Ferreira","year":"2025","journal-title":"ACS Omega"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","article-title":"Artificial Intelligence in Drug Development","volume":"31","author":"Zhang","year":"2025","journal-title":"Nat. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1021\/acs.molpharmaceut.8b00930","article-title":"Artificial Intelligence for Drug Discovery, Biomarker Development, and Generation of Novel Chemistry","volume":"15","author":"Zhavoronkov","year":"2018","journal-title":"Mol. Pharm."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/8\/1248\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T01:22:56Z","timestamp":1786324976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/8\/1248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":101,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ph19081248"],"URL":"https:\/\/doi.org\/10.3390\/ph19081248","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]}}}